The cost-cutting actions include a 33% decrease in headcount, from 43 to 29 employees, in the basic research and preclinical team and administrative support functions. Some outsourcing and
MedImmune will receive an upfront payment and has the potential to receive royalties on certain vaccine stockpiles or sales of other influenza products developed using the reverse genetics
Approximately 110 patients will be randomly assigned to receive either letrozole plus AS1402 or standard treatment with letrozole alone. The safety of the AS1402-letrozole combination will be evaluated
As a result, VGX Pharmaceuticals and VGX International, a Korean affiliate that is jointly developing VGX-1027, have initiated a multiple ascending dose study. VGX-1027 is an orally active,
The trial will focus on investigating the tolerability, safety, and therapeutic efficacy of multiple doses of 131I-TM601 when administered intravenously. This study follows the clinical confirmation in a
Elite will manufacture the product and will receive a share of the profits from the sale of the product upon commercialization. Bernard Berk, chairman and CEO for Elite,
The company intends to close all of the sales on October 3, 2008. As of September 29, 2008, excluding any proceeds from this offering, Repros had cash and
The board of directors also announced the appointment of Anthony Marucci, who has been serving as interim president and CEO since May 2008, as president and CEO of
Mr Keith is emeritus professor of obstetrics and gynecology at Northwestern University where he had taught more than 5000 medical students in a period of 29 years. Jim
The company said that the pivotal study is a multi-center US and EU evaluation of the Freedom Lumbar Disc in skeletally mature patients with single-level degenerative disc disease
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.